OmniAb (OABI) Interest Expenses (2021 - 2026)
OmniAb (OABI) posted quarterly Interest Expenses of $22.4 million for Q1 2026, up 73.38% year-over-year from $12.9 million in Q1 2025, and up 2227.13% quarter-over-quarter from $962000.0 in Q4 2025.
OmniAb (OABI) Interest Expenses (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Interest Expenses for 6 consecutive years, with $22.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 73.38% year-over-year to $22.4 million; the TTM figure through Mar 2026 stood at $22.4 million (up 73.38% YoY), while the FY2025 annual figure was $18.8 million, up 240.95% from the prior year.
- Interest Expenses grew to $22.4 million in Q1 2026 per OABI's latest filing, from $962000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $32.4 million in Q1 2023 and bottomed at -$2.0 million in Q4 2024.
- Historically, Interest Expenses has averaged $13.1 million across 5 years, with a median of $12.9 million in 2025.
- Annual changes were most pronounced in 2022 — Interest Expenses sank 413.88% — and 2023, when it surged 5554.45%.
- OmniAb's Interest Expenses stood at -$1.7 million in 2022, then jumped by 154.21% to $895000.0 in 2023, then slumped by 319.33% to -$2.0 million in 2024, then jumped by 149.01% to $962000.0 in 2025, then surged by 2227.13% to $22.4 million in 2026.
- Business Quant data shows OABI's Interest Expenses at $22.4 million in Q1 2026, $962000.0 in Q4 2025, and $12.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 21.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.42 Mn |
| Jun 30, 2026 | 21.42 Mn |
| Mar 31, 2026 | 22.39 Mn |
| Mar 31, 2026 | 22.39 Mn |
| Dec 31, 2025 | 962,000.00 |
| Dec 31, 2025 | 962,000.00 |
| Sep 30, 2025 | 12.91 Mn |
| Sep 30, 2025 | 12.91 Mn |
| Jun 30, 2025 | 25.18 Mn |
| Jun 30, 2025 | 25.18 Mn |
| Mar 31, 2025 | 12.91 Mn |
| Mar 31, 2025 | 12.91 Mn |
| Dec 31, 2024 | -1.96 Mn |
| Dec 31, 2024 | -1.96 Mn |
| Sep 30, 2024 | 13.41 Mn |
| Sep 30, 2024 | 13.41 Mn |
| Jun 30, 2024 | 28.73 Mn |
| Jun 30, 2024 | 28.73 Mn |
| Mar 31, 2024 | 29.60 Mn |
| Mar 31, 2024 | 29.60 Mn |